Bernie Sanders outraged once-free drug now costs $375,000

Sen. Bernie Sanders (I-Vt.) is demanding to know why a pharmaceutical company has slapped a $375,000 list price on a drug that patients used to get for free.

Sanders accused Patrick McEnany, president and CEO of Catalyst Pharmaceuticals Inc., of “a blatant fleecing of American taxpayers” and “an immoral exploitation of patients who need this medication” in a scathing letter Monday.

The drug, known as Firdapse, treats a rare autoimmune disease called Lambert-Eaton myasthenic syndrome, which fatigues and weakens muscles by causing the body to attack its own tissues.

RELATED: Bernie Sanders on Medicare

13 PHOTOS
Bernie Sanders' 'Medicare for All'
See Gallery
Bernie Sanders' 'Medicare for All'
Senator Bernie Sanders, an independent from Vermont, speaks during a health care bill news conference on Capitol Hill in Washington, D.C., U.S., on Wednesday, Sept. 13, 2017. Fifteen Senate Democrats are flirting with a single-payer health-care system that would expand Medicare coverage to all Americans, marking a shift within the party on what was once viewed as a politically treacherous issue that attracted little support from lawmakers. Photographer: Andrew Harrer/Bloomberg via Getty Images
Senator Elizabeth Warren, a Democrat from Massachusetts, left, listens as Senator Bernie Sanders, an independent from Vermont, speaks during a health care bill news conference on Capitol Hill in Washington, D.C., U.S., on Wednesday, Sept. 13, 2017. Fifteen Senate Democrats are flirting with a single-payer health-care system that would expand Medicare coverage to all Americans, marking a shift within the party on what was once viewed as a politically treacherous issue that attracted little support from lawmakers. Photographer: Andrew Harrer/Bloomberg via Getty Images
An attendee wears a Senator Bernie Sanders, an independent from Vermont, campaign t-shirt while holding a sign before the start of a health care bill news conference on Capitol Hill in Washington, D.C., U.S., on Wednesday, Sept. 13, 2017. Fifteen Senate Democrats are flirting with a single-payer health-care system that would expand Medicare coverage to all Americans, marking a shift within the party on what was once viewed as a politically treacherous issue that attracted little support from lawmakers. Photographer: Andrew Harrer/Bloomberg via Getty Images
Senator Kamala Harris, a Democrat from California, speaks as Senator Bernie Sanders, an independent from Vermont, left, listens during a health care bill news conference on Capitol Hill in Washington, D.C., U.S., on Wednesday, Sept. 13, 2017. Fifteen Senate Democrats are flirting with a single-payer health-care system that would expand Medicare coverage to all Americans, marking a shift within the party on what was once viewed as a politically treacherous issue that attracted little support from lawmakers. Photographer: Andrew Harrer/Bloomberg via Getty Images
Senator Bernie Sanders (I-VT) speaks during an event to introduce the "Medicare for All Act of 2017" on Capitol Hill in Washington, U.S., September 13, 2017. REUTERS/Yuri Gripas
A member of the audience holds up a placard as US Senator Bernie Sanders, Independent from Vermont, discusses Medicare for All legislation on Capitol Hill in Washington, DC, on September 13, 2017. The former US presidential hopeful introduced a plan for government-sponsored universal health care, a notion long shunned in America that has newly gained traction among rising-star Democrats. / AFP PHOTO / JIM WATSON (Photo credit should read JIM WATSON/AFP/Getty Images)
UNITED STATES - SEPTEMBER 13: Sen. Cory Booker, D-N.J., speaks during Sen. Bernie Sanders' event to introduce the Medicare for All Act of 2017 on Wednesday, Sept. 13, 2017. (Photo By Bill Clark/CQ Roll Call)
Senator Bernie Sanders (I-VT) speaks during an event to introduce the "Medicare for All Act of 2017" on Capitol Hill in Washington, U.S., September 13, 2017. REUTERS/Yuri Gripas
Senator Bernie Sanders (I-VT) speaks during an event to introduce the "Medicare for All Act of 2017" on Capitol Hill in Washington, U.S., September 13, 2017. REUTERS/Yuri Gripas
Members of the audience greet Senator Bernie Sanders (I-VT) during an event to introduce the "Medicare for All Act of 2017" on Capitol Hill in Washington, U.S., September 13, 2017. REUTERS/Yuri Gripas
Attendees hold signs while waiting for a health care bill news conference to begin on Capitol Hill in Washington, D.C., U.S., on Wednesday, Sept. 13, 2017. Fifteen Senate Democrats are flirting with a single-payer health-care system that would expand Medicare coverage to all Americans, marking a shift within the party on what was once viewed as a politically treacherous issue that attracted little support from lawmakers. Photographer: Andrew Harrer/Bloomberg via Getty Images
UNITED STATES - SEPTEMBER 13: The audience waves signs as Sen. Bernie Sanders, I-Vt., speaks during his event to introduce the Medicare for All Act of 2017 on Wednesday, Sept. 13, 2017. (Photo By Bill Clark/CQ Roll Call)
WASHINGTON, DC - SEPTEMBER 13: Supporters watch as U.S. Sen. Bernie Sanders (I-VT) (R) arrives at an event on health care September 13, 2017 on Capitol Hill in Washington, DC. Sen. Sanders held an event to introduce the Medicare for All Act of 2017. (Photo by Alex Wong/Getty Images)
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE

The drug had been available at no cost for two decades under the name 3,4-DAP from Jacobus Pharmaceutical as part of the Food and Drug Administration’s compassionate use program. The drug, though unapproved specifically for Lambert-Eaton myasthenic syndrome, often was prescribed by doctors for the condition.

Catalyst in November won expedited FDA approval to sell Fidapse as the first treatment for Lambert-Eaton myasthenic syndrome. A month later, the company announced the list price for a year’s treatment: $375,000.

Now, Sanders is asking “how many patients will suffer or die” because they can’t afford the medication.

“This is no longer a speculative issue of pricing ― this is a real issue, and it is an access issue,” the lawmaker wrote. “By setting such a high price and forcing production and distribution of the older, inexpensive version to cease, you are threatening access that patients had to a cheap version of this product, and handing a completely unwarranted bill to American taxpayers.”

Sanders noted that Catalyst has reportedly said many patients will be charged only around $10 a month for the medication. Nevertheless, he asked the company to provide the average price, and whether patients are paying high deductibles for the medicine before their insurance coverage kicks in.

Catalyst told CNN in a statement that it plans to respond to the letter soon.

  • This article originally appeared on HuffPost.
Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.